Anticoagulant Reversal Drugs Market Report

The main factors affecting the growth of the market include an increase in the global prevalence of several cardiovascular diseases, atrial fibrillation, an increase in intracranial and gastrointestinal haemorrhages and an ageing population lead to higher prescription of anticoagulant drugs. According to CDC figures, 805,000 people in the United States experience a heart attack each year, with 605,000 of them being first-time heart attacks and 200,000 being caused by previous heart attacks.  The rising prevalence of cardiovascular disorders in developed countries such as the United States is expected to drive market development over the forecast period. The American Heart Association estimates that the general prevalence of atrial fibrillation in the United States is 1% to 2%. According to the CDC, over 12.1 million individuals will have atrial fibrillation by 2030. In accordance with the CDC, between 60,000 and 100,000 Americans die annually from deep vein thrombosis or pulmonary embolism. For instance, the American College of Cardiology stated in its June 2022 research that for atrial fibrillation, there would be a developing novel drug development wave that will meet the requirement for anticoagulants in the coming years.

Strict regulation of market for anticoagulant reversal drugs is becoming the channel of the given market by the means of application of the stringent provisions for the drugs’ registration, as well as by the elevated criteria of the safety and efficacy of the drugs. This is because of the free-standing bodies that scrutinize such products on approval such as the Food and Drug Administration ‘FDA’ and Independent Triangle Society for Medical Award ‘ISMA’ set cut-off standards of clinical sessions and utmost proof of safety of the product before it is taken to the market. Attributed to extensive study, some of the facts that could have been expected to restrain the growth of the market between the years 2021-2027 may include the high cost of anticoagulant reversal drugs. There are side effects which are bad that accompany the medicines and they often affect people particularly the elderly. It may increase the bleeding level beyond the acceptable level as it is being applied in the course of the treatment while the higher amount has several implications. Thus, the negative outcomes of the drugs do not allow for the appearance of the counter discourse toward the enlargement of the global market. For instance, in March 2023, Ascend Laboratories LLC will compete for the top position in producing generic drugs by. Because N-nitroso-dabigatran has been found in the volunteered Dabigatran Etexilate Capsules, USP 75 mg and 150 mg, batches of US lots are being recalled.

Positive trends as new innovations, product launches, and FDA clearances that introduce the effective solutions are the major stimuli for the market growth. The healthcare facilities are using cash to affect research and growth of new products aiming at satisfying the consumer needs and improving patient health outcomes. The FDA approvals ascertain that these products are safe to use and will launch them to the market for sale. This approval positively influences the level of confidence among the consumers and the healthcare providers, while at the same time promoting faster rates of adoption. For example, in July 2023, a product named Balfaxar that is part of Octapharma plc’s prothrombin complex concentrate gets approval from FDA for reversal of warfarin in emergency surgery. Balfaxar replenishes the reduced clotting factors by the administration of warfarin treatment. Balfaxar is an inactive 4F-PCC, obtained from plasma, which contains a set of vitamin K-dependent clotting factors including; Factor II (prothrombin), Factor VII, Factor IX, Factor X, antithrombotic Proteins C and S.

The United States holds the majority of the North American market. High healthcare expenditure and favourable healthcare reimbursement policies for expensive medicines are the primary factors driving its rise. The United States has the largest market share in the region, owing to the USFDA's accelerated drug approval initiative and the Centres for Disease Control and Prevention's launch of various prevention programmes and awareness workshops for blood disorders, which are expected to drive market growth in this region. Furthermore, the alarming number of cardiovascular disorders in the United States propels the market. According to the CDC, 1 person dies from cardiovascular disease every 34 seconds in the United States. As per the American College of Cardiology, coronary events affect approximately 1,055,000 people each year, with 720,000 new and 335,000 recurrent coronary events. Given the aforementioned factors, the anticoagulant reversal drugs market in North America is expected to develop considerably throughout the forecast period.